Prevalence, clinical characteristics and outcomes of heart failure patients with or without isolated or combined mitral and tricuspid regurgitation: An analysis from the ESC-HFA Heart Failure Long-Term Registry.
Heart failure
Left ventricular ejection fraction
Mitral regurgitation
Tricuspid regurgitation
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
04
06
2023
received:
06
04
2023
accepted:
11
06
2023
medline:
9
8
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Mitral regurgitation (MR) and tricuspid regurgitation (TR) are common in patients with heart failure (HF). The aim of this study was to investigate prevalence, clinical characteristics and outcomes of patients with or without isolated or combined MR and TR across the entire HF spectrum. The ESC-HFA EORP HF Long-Term Registry is a prospective, multicentre, observational study including patients with HF and 1-year follow-up data. Outpatients without aortic valve disease were included and stratified according to isolated or combined moderate/severe MR and TR. Among 11 298 patients, 7541 (67%) had no MR/TR, 1931 (17%) isolated MR, 616 (5.5%) isolated TR and 1210 (11%) combined MR/TR. Baseline characteristics were differently distributed across MR/TR categories. Compared to HF with reduced ejection fraction, HF with mildly reduced ejection fraction was associated with a lower risk of isolated MR (odds ratio [OR] 0.69; 95% confidence interval [CI] 0.60-0.80), and distinctly lower risk of combined MR/TR (OR 0.51; 95% CI 0.41-0.62). HF with preserved ejection fraction (HFpEF) was associated with a distinctly lower risk of isolated MR (OR 0.42; 95% CI 0.36-0.49), and combined MR/TR (OR 0.59; 95% 0.50-0.70), but a distinctly increased risk of isolated TR (OR 1.94; 95% CI 1.61-2.33). All-cause death, cardiovascular death, HF hospitalization and combined outcomes occurred more frequently in combined MR/TR, isolated TR and isolated MR versus no MR/TR. The highest incident rates were observed in isolated TR and combined MR/TR. In a large cohort of outpatients with HF, prevalence of isolated and combined MR and TR was relatively high. Isolated TR was driven by HFpEF and was burdened by an unexpectedly poor outcome.
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1071Informations de copyright
© 2023 European Society of Cardiology.
Références
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1574-1585. https://doi.org/10.1002/ejhf.813
Bartko PE, Hulsmann M, Hung J, Pavo N, Levine RA, Pibarot P, et al. Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. Eur Heart J. 2020;41:2799-2810. https://doi.org/10.1093/eurheartj/ehaa129
Tribouilloy C, Bohbot Y, Kubala M, Ruschitzka F, Popescu B, Wendler O, et al. Characteristics, management, and outcomes of patients with multiple native valvular heart disease: A substudy of the EURObservational Research Programme Valvular Heart Disease II Survey. Eur Heart J. 2022;43:2756-2766. https://doi.org/10.1093/eurheartj/ehac209
Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, et al.; EORP VHD II Investigators. Contemporary presentation and management of valvular heart disease: The EURObservational Research Programme Valvular Heart Disease II Survey. Circulation. 2019;140:1156-1169. https://doi.org/10.1161/CIRCULATIONAHA.119.041080
Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, et al. Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF. Eur J Heart Fail. 2021;23:1750-1758. https://doi.org/10.1002/ejhf.2276
Goliasch G, Bartko PE, Pavo N, Neuhold S, Wurm R, Mascherbauer J, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J. 2018;39:39-46. https://doi.org/10.1093/eurheartj/ehx402
Bartko PE, Heitzinger G, Pavo N, Heitzinger M, Spinka G, Prausmuller S, et al. Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: Observational cohort study. BMJ. 2021;373:n1421. https://doi.org/10.1136/bmj.n1421
Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart. 2011;97:1675-1680. https://doi.org/10.1136/hrt.2011.225789
Grigioni F, Detaint D, Avierinos JF, Scott C, Tajik J, Enriquez-Sarano M. Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. J Am Coll Cardiol. 2005;45:260-267. https://doi.org/10.1016/j.jacc.2004.10.030
Topilsky Y, Inojosa JM, Benfari G, Vaturi O, Maltais S, Michelena H, et al. Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction. Eur Heart J. 2018;39:3584-3592. https://doi.org/10.1093/eurheartj/ehy434
Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging. 2020;21:157-165. https://doi.org/10.1093/ehjci/jez216
Benfari G, Antoine C, Miller WL, Thapa P, Topilsky Y, Rossi A, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. 2019;140:196-206. https://doi.org/10.1161/CIRCULATIONAHA.118.038946
Messika-Zeitoun D, Verta P, Gregson J, Pocock SJ, Boero I, Feldman TE, et al. Impact of tricuspid regurgitation on survival in patients with heart failure: A large electronic health record patient-level database analysis. Eur J Heart Fail. 2020;22:1803-1813. https://doi.org/10.1002/ejhf.1830
Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15:808-817. https://doi.org/10.1093/eurjhf/hft050
Bartko PE, Arfsten H, Heitzinger G, Pavo N, Winter MP, Toma A, et al. Natural history of bivalvular functional regurgitation. Eur Heart J Cardiovasc Imaging. 2019;20:565-573. https://doi.org/10.1093/ehjci/jey178
Bartko PE, Dal-Bianco JP, Guerrero JL, Beaudoin J, Szymanski C, Kim DH, et al.; Leducq Transatlantic Mitral Network. Effect of losartan on mitral valve changes after myocardial infarction. J Am Coll Cardiol. 2017;70:1232-1244. https://doi.org/10.1016/j.jacc.2017.07.734
Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. 2019;12:433-442. https://doi.org/10.1016/j.jcmg.2018.06.014
Guta AC, Badano LP, Tomaselli M, Mihalcea D, Bartos D, Parati G, et al. The pathophysiological link between right atrial remodeling and functional tricuspid regurgitation in patients with atrial fibrillation: A three-dimensional echocardiography study. J Am Soc Echocardiogr. 2021;34:585-94.e1. https://doi.org/10.1016/j.echo.2021.01.004
Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention. 2021;17:791-808. https://doi.org/10.4244/EIJ-D-21-00695
Florescu DR, Muraru D, Florescu C, Volpato V, Caravita S, Perger E, et al. Right heart chambers geometry and function in patients with the atrial and the ventricular phenotypes of functional tricuspid regurgitation. Eur Heart J Cardiovasc Imaging. 2022;23:930-940. https://doi.org/10.1093/ehjci/jeab211
Prihadi EA, van der Bijl P, Gursoy E, Abou R, Mara Vollema E, Hahn RT, et al. Development of significant tricuspid regurgitation over time and prognostic implications: New insights into natural history. Eur Heart J. 2018;39:3574-3581. https://doi.org/10.1093/eurheartj/ehy352
Wang TKM, Akyuz K, Mentias A, Kirincich J, Duran Crane A, Xu S, et al. Contemporary etiologies, outcomes, and novel risk score for isolated tricuspid regurgitation. JACC Cardiovasc Imaging. 2022;15:731-744. https://doi.org/10.1016/j.jcmg.2021.10.015
Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19:100-116. https://doi.org/10.1038/s41569-021-00605-5
Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: A nationwide cohort study. Circ Heart Fail. 2017;10:e003875. https://doi.org/10.1161/CIRCHEARTFAILURE.117.003875
Chang CC, Veen KM, Hahn RT, Bogers A, Latib A, Oei FBS, et al. Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: A state-of-the-art expert review. Eur Heart J. 2020;41:1932-1940. https://doi.org/10.1093/eurheartj/ehz614
Zaccone G, Di Pasquale M, Fiorina C, Curello S, Metra M, Adamo M. Transcatheter therapies for tricuspid valve regurgitation. J Cardiovasc Med (Hagerstown). 2020;21:964-974. https://doi.org/10.2459/JCM.0000000000001062
Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74:2998-3008. https://doi.org/10.1016/j.jacc.2019.09.028
Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al.; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632. https://doi.org/10.1093/eurheartj/ehab395